Silverarc Capital Management’s Rocket Pharmaceuticals Warrant RCKTW Stock Holding History

Silverarc Capital Management’s Portfolio RCKTW Stock Details RCKTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.16K	Hold	104,828	–	–	﹤0.01%	73
2025 Q4	$2.55K	Hold	104,828	–	–	﹤0.01%	68
2025 Q3	$4.11K	Hold	104,828	–	–	﹤0.01%	82
2025 Q2	$3.02K	Hold	104,828	–	–	﹤0.01%	65
2025 Q1	$4.93K	Hold	104,828	–	–	﹤0.01%	69
2024 Q4	$3.6K	Hold	104,828	–	–	﹤0.01%	61
2024 Q3	$6.76K	Hold	104,828	–	–	﹤0.01%	71
2024 Q2	$6.36K	Hold	104,828	–	–	﹤0.01%	70
2024 Q1	$31.4K	Hold	104,828	–	–	0.01%	76
2023 Q4	$51.4K	Hold	104,828	–	–	0.02%	67
2023 Q3	$17.8K	Hold	104,828	–	–	0.01%	79
2023 Q2	$19.9K	Hold	104,828	–	–	0.01%	81
2023 Q1	$11.5K	Buy	+104,828	New	+$20.2K	﹤0.01%	71

Other funds holding RCKTW

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Silverarc Capital Management's RCKTW Position: Q1 2026 in Review

Silverarc Capital Management held its Rocket Pharmaceuticals Warrant (RCKTW) position steady in Q1 2026 at 104,828 shares worth $2.16K. The position accounts for ﹤0.01% of the portfolio, ranked #73.

Silverarc Capital Management first reported a position in RCKTW in Q1 2023 and has held it in 13 quarters since. The position peaked at $51.4K in Q4 2023. 10 funds tracked by Wall St. Rank hold RCKTW as of Q1 2026.

Silverarc Capital Management held 104,828 shares of Rocket Pharmaceuticals Warrant worth $2.16K as of Q1 2026.
Silverarc Capital Management left its Rocket Pharmaceuticals Warrant share count unchanged in Q1 2026.
Rocket Pharmaceuticals Warrant made up ﹤0.01% of Silverarc Capital Management's portfolio in Q1 2026, its #73 holding.
Silverarc Capital Management first reported a position in Rocket Pharmaceuticals Warrant in Q1 2023 and has held it in 13 quarters since.
Silverarc Capital Management's Rocket Pharmaceuticals Warrant position peaked at $51.4K in Q4 2023.
10 funds tracked by Wall St. Rank held Rocket Pharmaceuticals Warrant as of Q1 2026.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.